Sotorasib in Advanced KRAS p.G12C-Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)

被引：0

作者：

Awad, M. M. ^{[1
]}

Pelizzari, G. ^{[2
]}

Stevenson, J. ^{[3
]}

Majem, M. ^{[4
]}

Ferreira, C. Gil ^{[5
]}

Petty, W. ^{[6
]}

Arriola, E. ^{[7
]}

De Castro, J. ^{[8
]}

Morbeck, I. ^{[9
]}

Bauman, J. ^{[10
]}

Toschi, L. ^{[11
]}

Zer, A. ^{[12
]}

Metro, G. ^{[13
]}

Kalmadi, S. ^{[14
]}

Azkarate, A. ^{[15
]}

Xia, C. ^{[16
]}

Meloni, A. ^{[16
]}

Obiozor, C. ^{[16
]}

Hsu, H. ^{[16
]}

Varrieur, T. ^{[16
]}

Ardito-Abraham, C. ^{[16
]}

Maimon, N. ^{[17
]}

Novello, S. ^{[18
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Azienda Sanitaria Univ Friuli Cent, Dipartimento Oncol Udine, Udine, Italy

[3] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH USA

[4] Hosp Santa Creu i Sant Pau, Dept Med Oncol, Barcelona, Spain

[5] Oncoclin Inst Res & Educ, Dept Educ & Res, Rio De Janeiro, Brazil

[6] Wake Forest Univ, Dept Hematol & Oncol, Sch Med, Winston Salem, NC USA

[7] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[8] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain

[9] Hosp Sirio Libanes, Ctr Oncol, Ctr Oncol Asa Sul, Brasilia, DF, Brazil

[10] Fox Chase Canc Ctr, Dept Hematol Oncol, Main Campus, Philadelphia, PA USA

[11] Ist Clin Humanitas, Dept Med Oncol, Rozzano, Italy

[12] Davidoff Canc Ctr, Rabin Med Ctr, Thorac Canc Serv, Petah Tiqwa, Israel

[13] Osped S Maria Misericordia, Dept Med Oncol, Perugia, Italy

[14] Ironwood Canc & Res Ctr, Dept Hematol & Med Oncol, Chandler, AZ USA

[15] Hosp Univ Son Espases, Dept Med Oncol, Palma de Mallorca, Spain

[16] Amgen Inc, Thousand Oaks, CA USA

[17] Sackler Sch Med, Div Oncol, Meir Med Ctr, Oncol Serv, Rishon Leziyyon, Israel

[18] Univ Torino Orbassano, Dept Oncol, Orbassano, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PP01.17

引用

页码：E17 / E17

页数：1

共 50 条

[21] Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain Metastases
Cortinovis, Diego
Delmonte, Angelo
Chiari, Rita
Catino, Annamaria
Grossi, Francesco
Noberasco, Cristina
Gelsomino, Francesco
Gilli, Marina
Proto, Claudia
Parra, Hector Soto
Migliorino, Maria Rita
Bonomi, Lucia
Tassinari, Davide
Frassoldati, Antonio
Albanese, Valeria
Fadda, Giovanni
De Galitiis, Federica
Finocchiaro, Giovanna
Cognetti, Francesco
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1336 - S1336
[22] Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
Inno, Alessandro
Marchetti, Fabiana
Valerio, Matteo
Levra, Niccolo Giaj
Alongi, Filippo
Foti, Giovanni
Gori, Stefania
DRUG TARGET INSIGHTS, 2023, 17 : 90 - 91
[23] Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"
Jiang, Yanfang
Zhang, Lei
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09) : e43 - e43
[24] CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
Li, B. T.
Falchook, G. S.
Durm, G. A.
Burns, T. F.
Skoulidis, F.
Ramalingam, S. S.
Spira, A.
Bestvina, C. M.
Goldberg, S. B.
Veluswamy, R.
Iams, W. T.
Chiappori, A. A.
Lemech, C. R.
Meloni, A. R.
Ebiana, V.
Dai, T.
Gauto, D. M.
Varrieur, T. L.
Snyder, W. J.
Govindan, R.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S10 - S11
[25] A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors
Ramalingam, Suresh
Fakih, Marwan
Strickler, John
Govindan, Ramaswamy
Li, Bob T.
Goldberg, Sarah
Gandara, David
Burns, Timothy
Barve, Minal
Shu, Catherine
Frank, Richard
Sohal, Davendra
Jafarinasabian, Pegah
Dai, Tian
Mather, Omar
Hong, David
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[26] Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
Hochmair, Maximilian J.
Vermaelen, Karim
Mountzios, Giannis
Carcereny, Enric
Dooms, Christophe
Lee, Se-Hoon
Morocz, Eva
Kato, Terufumi
Ciuleanu, Tudor-Eliade
Dy, Grace K.
Parente, Barbara
O'Byrne, Kenneth J.
Chu, Quincy S.
De Castro Junior, Gilberto
Girard, Nicolas
Snyder, Wendy
Tran, Qui
Kormany, William
Houk, Brett
Mehta, Bhakti
Curioni-Fontecedro, Alessandra
EUROPEAN JOURNAL OF CANCER, 2024, 208
[27] EFFICACY AND SAFETY DATA FROM PATIENTS WITH ADVANCED MELANOMA AND BRAIN METASTASES PARTICIPATING IN THE EUROPEAN IPILIMUMAB EXPANDED ACCESS PROGRAMME (EAP) IN ITALY
Queirolo, P.
Simeone, E.
De Galitiis, F.
Di Guardo, L.
Di Giacomo, A. M.
Marconcini, R.
Ferraresi, V.
De Rosa, F.
Guida, M.
Stragliotto, S.
ANNALS OF ONCOLOGY, 2012, 23 : 369 - 369
[28] Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC
Zhou, Katherine I.
Lin, Chenyu
Tseng, Chin-Lin
Ramnath, Nithya
Dowell, Jonathan E.
Kelley, Michael J.
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (05):
[29] Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain Metastases
Crino, L.
Bidoli, P.
Ulivi, P.
Minenza, E.
Cortesi, E.
Garassino, M.
Cappuzzo, F.
Grossi, F.
Tonini, G.
Sarobba, M. G.
Pinotti, G.
Numico, G.
Samaritani, R.
Ciuffreda, L.
Frassoldati, A.
Bregni, M. B.
Santo, A.
Piantedosi, F.
Illiano, A.
De Marinis, F.
Delmonte, A.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1914 - S1914
[30] A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"
Ernst, Sophie M.
von der Thusen, Jan H.
Dubbink, Hendrikus J.
Dingemans, Anne-Marie C.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09)

← 1 2 3 4 5 →